NCT00781976View on ClinicalTrials.gov

Antiviral Activity of AZD7295 in HCV Carriers

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Hepatitis C

Interventions

DRUG

AZD7295

700mg per day maximum

DRUG

Placebo

matched placebo

Trial Locations (1)

Unknown

Prof Ed Gane, Auckland

Sponsors

Lead Sponsor

Arrow Therapeutics

All Listed Sponsors

lead

Arrow Therapeutics

INDUSTRY

NCT00781976 - Antiviral Activity of AZD7295 in HCV Carriers | Biotech Hunter | Biotech Hunter